75 related articles for article (PubMed ID: 30138536)
1. RELT negatively regulates the early phase of the T-cell response in mice.
Choi BK; Kim SH; Kim YH; Lee DG; Oh HS; Han C; Kim YI; Jeon Y; Lee H; Kwon BS
Eur J Immunol; 2018 Oct; 48(10):1739-1749. PubMed ID: 30138536
[TBL] [Abstract][Full Text] [Related]
2. RELT, a new member of the tumor necrosis factor receptor superfamily, is selectively expressed in hematopoietic tissues and activates transcription factor NF-kappaB.
Sica GL; Zhu G; Tamada K; Liu D; Ni J; Chen L
Blood; 2001 May; 97(9):2702-7. PubMed ID: 11313261
[TBL] [Abstract][Full Text] [Related]
3. Cutting edge: selective impairment of CD8+ T cell function in mice lacking the TNF superfamily member LIGHT.
Tamada K; Ni J; Zhu G; Fiscella M; Teng B; van Deursen JM; Chen L
J Immunol; 2002 May; 168(10):4832-5. PubMed ID: 11994431
[TBL] [Abstract][Full Text] [Related]
4. Persistence, immune specificity, and functional ability of murine mutant ras epitope-specific CD4(+) and CD8(+) T lymphocytes following in vivo adoptive transfer.
Bristol JA; Schlom J; Abrams SI
Cell Immunol; 1999 May; 194(1):78-89. PubMed ID: 10357883
[TBL] [Abstract][Full Text] [Related]
5. Activation of natural killer T cells by alpha-galactosylceramide rapidly induces the full maturation of dendritic cells in vivo and thereby acts as an adjuvant for combined CD4 and CD8 T cell immunity to a coadministered protein.
Fujii S; Shimizu K; Smith C; Bonifaz L; Steinman RM
J Exp Med; 2003 Jul; 198(2):267-79. PubMed ID: 12874260
[TBL] [Abstract][Full Text] [Related]
6. Anti-CD137 antibodies in the treatment of autoimmune disease and cancer.
Mittler RS; Foell J; McCausland M; Strahotin S; Niu L; Bapat A; Hewes LB
Immunol Res; 2004; 29(1-3):197-208. PubMed ID: 15181282
[TBL] [Abstract][Full Text] [Related]
7. CD8 T cell priming in the presence of IFN-α renders CTLs with improved responsiveness to homeostatic cytokines and recall antigens: important traits for adoptive T cell therapy.
Hervas-Stubbs S; Mancheño U; Riezu-Boj JI; Larraga A; Ochoa MC; Alignani D; Alfaro C; Morales-Kastresana A; Gonzalez I; Larrea E; Pircher H; Le Bon A; Lopez-Picazo JM; Martín-Algarra S; Prieto J; Melero I
J Immunol; 2012 Oct; 189(7):3299-310. PubMed ID: 22925929
[TBL] [Abstract][Full Text] [Related]
8. Expression and function of 4-1BB during CD4 versus CD8 T cell responses in vivo.
Dawicki W; Watts TH
Eur J Immunol; 2004 Mar; 34(3):743-751. PubMed ID: 14991604
[TBL] [Abstract][Full Text] [Related]
9. CD8(+) T activation attenuates CD4(+) T proliferation through dendritic cells modification.
Chen D; Wang Y; Wang H; Wu Y; Xia S; Zhang M
Cell Immunol; 2015 Aug; 296(2):138-48. PubMed ID: 26022412
[TBL] [Abstract][Full Text] [Related]
10. PD-L1-deficient mice show that PD-L1 on T cells, antigen-presenting cells, and host tissues negatively regulates T cells.
Latchman YE; Liang SC; Wu Y; Chernova T; Sobel RA; Klemm M; Kuchroo VK; Freeman GJ; Sharpe AH
Proc Natl Acad Sci U S A; 2004 Jul; 101(29):10691-6. PubMed ID: 15249675
[TBL] [Abstract][Full Text] [Related]
11. GITR, a member of the TNF receptor superfamily, is costimulatory to mouse T lymphocyte subpopulations.
Ronchetti S; Zollo O; Bruscoli S; Agostini M; Bianchini R; Nocentini G; Ayroldi E; Riccardi C
Eur J Immunol; 2004 Mar; 34(3):613-622. PubMed ID: 14991590
[TBL] [Abstract][Full Text] [Related]
12. Synergistic enhancement of antitumor immunity with adoptively transferred tumor-specific CD4+ and CD8+ T cells and intratumoral lymphotactin transgene expression.
Huang H; Li F; Gordon JR; Xiang J
Cancer Res; 2002 Apr; 62(7):2043-51. PubMed ID: 11929823
[TBL] [Abstract][Full Text] [Related]
13. 4-1BB and OX40 stimulation enhance CD8 and CD4 T-cell responses to a DNA prime, poxvirus boost vaccine.
Munks MW; Mourich DV; Mittler RS; Weinberg AD; Hill AB
Immunology; 2004 Aug; 112(4):559-66. PubMed ID: 15270726
[TBL] [Abstract][Full Text] [Related]
14. GITR activation induces an opposite effect on alloreactive CD4(+) and CD8(+) T cells in graft-versus-host disease.
Muriglan SJ; Ramirez-Montagut T; Alpdogan O; Van Huystee TW; Eng JM; Hubbard VM; Kochman AA; Tjoe KH; Riccardi C; Pandolfi PP; Sakaguchi S; Houghton AN; Van Den Brink MR
J Exp Med; 2004 Jul; 200(2):149-57. PubMed ID: 15249593
[TBL] [Abstract][Full Text] [Related]
15. Enhancement of MHC class I-stimulated alloresponses by TNF/TNF receptor (TNFR)1 interactions and of MHC class II-stimulated alloresponses by TNF/TNFR2 interactions.
Brown GR; Thiele DL
Eur J Immunol; 2000 Oct; 30(10):2900-7. PubMed ID: 11069072
[TBL] [Abstract][Full Text] [Related]
16. Tumor Necrosis Factor Receptor 2 Restricts the Pathogenicity of CD8(+) T Cells in Mice With Colitis.
Punit S; Dubé PE; Liu CY; Girish N; Washington MK; Polk DB
Gastroenterology; 2015 Oct; 149(4):993-1005.e2. PubMed ID: 26072395
[TBL] [Abstract][Full Text] [Related]
17. Tumor-induced interleukin 10 suppresses the ability of splenic dendritic cells to stimulate CD4 and CD8 T-cell responses.
Yang AS; Lattime EC
Cancer Res; 2003 May; 63(9):2150-7. PubMed ID: 12727833
[TBL] [Abstract][Full Text] [Related]
18. A subclass of dendritic cells regulates the response of naive CD8 T cells by limiting their IL-2 production.
Kronin V; Winkel K; Süss G; Kelso A; Heath W; Kirberg J; von Boehmer H; Shortman K
J Immunol; 1996 Nov; 157(9):3819-27. PubMed ID: 8892611
[TBL] [Abstract][Full Text] [Related]
19. The glucocorticoid-induced tumor necrosis factor receptor-related gene modulates the response to Candida albicans infection.
Agostini M; Cenci E; Pericolini E; Nocentini G; Bistoni G; Vecchiarelli A; Riccardi C
Infect Immun; 2005 Nov; 73(11):7502-8. PubMed ID: 16239552
[TBL] [Abstract][Full Text] [Related]
20. Melanoma-infiltrating dendritic cells induce protective antitumor responses mediated by T cells.
Preynat-Seauve O; Contassot E; Schuler P; French LE; Huard B
Melanoma Res; 2007 Jun; 17(3):169-76. PubMed ID: 17505262
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
